Investor Presentaiton

Biosimilars can lower cost and increase access to biologics, globally Biosimilars in the U.S. alone are expected to result in $42Bn of savings over the next 5 years1 Biosimilars are therapeutically equivalent to biologics and provide a more cost-effective alternative to health systems, payers and patients; And can encourage innovation through competition Europe is the most mature biosimilar market reaching €9.7Bn in 2021 generating €30Bn of savings across Europe² Global Savings from biosimilars are expected to exceed $290Bn in cumulative spending through 20272 7 Sources: 1 IQVIA Institute 2- IQVIA Institute alvotech © ALVOTECH. ALL RIGHTS RESERVED

View entire presentation